AI Article Synopsis
- Advances in therapies have led to higher survival rates for breast cancer patients, particularly with hormone receptor-positive disease, where adjuvant endocrine therapy plays a key role.
- However, this therapy can cause significant side effects that impact treatment adherence and overall quality of life, especially in premenopausal women due to sudden estrogen suppression.
- The review discusses various strategies—both pharmacological and non-pharmacological—to manage these side effects, aiming to restore the quality of life for cancer survivors.
Article Abstract
The growing availability of more effective therapies has contributed to an increased survival of patients with breast cancer. In hormone receptor-positive early disease, increased survival is strongly correlated with the use of adjuvant endocrine therapy, but this therapy can cause side-effects that have major consequences in terms of treatment adherence and patients' quality of life. In premenopausal breast cancer survivors, these side-effects might be even more prominent due to the abrupt suppression of oestrogen associated with the most intense endocrine therapies. An important ambition of cancer care in the 21st century is to recover pre-cancer quality of life and emotional and social functions, which is only possible through the mitigation of the side-effects of anticancer treatments. This Review presents a comprehensive summary of the efficacy and safety data of the available interventions (hormonal and non-hormonal pharmacological strategies, non-pharmacological approaches, and complementary and alternative medicine) to control selected side-effects associated with adjuvant endocrine therapy (hot flashes, sexual dysfunction, weight gain, musculoskeletal symptoms, and fatigue), providing updated, evidence-based approaches for their management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(20)30666-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFPerioperative chemotherapy strategies in diffuse gastric cancer.
World J Gastrointest Surg
January 2025
Department of Surgery, Division of Endocrine & Minimally Invasive Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10128, United States.
This study reviews the findings of a recent study by Li , which demonstrated that perioperative chemotherapy benefits patients with diffuse-type gastric cancer compared to surgery alone. Despite potential biases, the study supports the inclusion of perioperative chemotherapy in treatment guidelines. Neoadjuvant and adjuvant chemotherapy may also provide similar survival outcomes, allowing for flexible treatment planning.
View Article and Find Full Text PDFPrediction of difficult mask ventilation in Thai adult patients undergoing elective surgery using ultrasound of distance from skin to hyoid bone, and from skin to thyroid isthmus: a prospective cohort observational study.
BMC Anesthesiol
January 2025
Department of Anesthesiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, 90110, Thailand.
Background: A previous study showed that airway ultrasound, specifically the distance from the skin to the hyoid bone (DSHB), may be correlated with a higher risk of difficult mask ventilation (DMV). However, the study was conducted in Italy and lacks data for the Asian and Thai populations. This study aimed to predict DMV using pre-operative ultrasonography to measure the DSHB and from the skin to the thyroid isthmus (DSTI) in Thai patients undergoing elective surgery under general anesthesia.
View Article and Find Full Text PDFAdjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.
Endocrine
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Purpose: Adrenocortical carcinoma (ACC) is a rare malignancy known for high rates of recurrence and poor prognosis. Previous studies revealed controversial roles of adjuvant radiation therapy (RT) in patient management. This study aimed to investigate the role of adjuvant RT in postoperative ACC patients.
View Article and Find Full Text PDFAnticancer-Drug-Related Cardiotoxicity from Adjuvant Goserelin and Tamoxifen Therapy.
J Clin Med
January 2025
Laboratory of Epidemiological and Clinical Cardiology, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
Breast cancer is a prevalent malignancy with rising incidence globally. Advances in endocrine therapy have improved outcomes for premenopausal women with hormone receptor-positive breast cancer. However, these treatments may induce menopause-like states, potentially elevating cardiovascular risks, including left ventricular (LV) dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!